Is INBS undervalued? Our fair value estimate
Intelligent Bio Solutions Inc. · Healthcare · NCM
How we got here
The estimate is computed from INBS's reported fundamentals, with a growth assumption that is deliberately capped: small changes to an uncapped growth or terminal assumption can justify any price, and a number that can justify anything means nothing. These are the inputs the model holds for INBS today; the exact method, and where it goes wrong, is on the methodology page.
The trailing growth rate informs the growth assumption, which the model caps deliberately: uncapped growth assumptions can justify any price.
Wall Street's published earnings growth forecast, used as context for the capped growth assumption, never swallowed whole.
Margins tell the model how much of each unit of revenue survives as profit, and how much room there is for that to erode.
Persistent high returns on capital are what a moat looks like in the accounts, and they feed the moat score alongside the valuation.
A volatility measure against the wider market. A jumpier share earns a larger discount for risk, which lowers the estimate.
Leverage haircuts the estimate: debt claims cash before shareholders do, and it turns bad years into dangerous ones.
Wall Street's number, next to ours
The mean analyst price target for INBS is USD12.00 across 1 analysts, which implies +585.7% from the current price. Our estimate is USD3.85. They answer different questions: an analyst target is a 12-month price prediction averaged across banks; ours is a model's view of what the business is worth, with every assumption published. When they disagree, at least one of us is wrong.
Healthcare peers, by our rating
The same model, run on the highest-rated names in the same sector. A gap to fair value is only comparable when the method behind it is identical, which here it is.
Common questions
Is Intelligent Bio Solutions Inc. (INBS) undervalued?
On our model, INBS at USD1.75 trades 120% below our fair value estimate of USD3.85, so it screens as undervalued today. That is one model's answer, not a recommendation: a fair value estimate is an argument about the future, and the market is frequently right about why something is cheap.
What is the fair value of INBS?
Our current fair value estimate for Intelligent Bio Solutions Inc. is USD3.85 per share. For comparison, the mean Wall Street analyst price target is USD12.00 across 1 analysts; that is their number, computed differently from ours. The estimate moves as prices and fundamentals move.
How is INBS's fair value calculated?
From Intelligent Bio Solutions Inc.'s reported fundamentals: earnings power, a deliberately capped growth assumption, and a discount for balance sheet and volatility risk. The full method, including its known weaknesses, is published on our methodology page, and the interactive Valuation Lab lets you change every assumption and watch the value move.
Disagree with an assumption? Good. The Valuation Lab on the INBS app page puts every input of this model on a slider, including a reverse DCF that shows the growth the market is currently pricing in.
A fair value estimate is a model output computed from company filings and market data, refreshed daily; quotes are delayed. It is educational information, not financial advice and not a recommendation to buy or sell anything. Read the full disclaimer.